A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma

The goal of this study is to assess the safety and effectiveness of Dostarlimab compared to Placebo in adult participants with Head and Neck Squamous Cell Carcinoma (HNSCC)

Trial Details

NCT ID
NCT06256588
Phase
PHASE3
Sponsor
GlaxoSmithKline
Status
RECRUITING
Cancer Type
Head and Neck Cancer
Interventions
  • Dostarlimab
  • Placebo
Locations (sample)
  • Jonesboro, Arkansas, United States|35.8423,-90.70428
  • Los Angeles, California, United States|34.05223,-118.24368
  • Solvang, California, United States|34.59582,-120.13765
  • Stockton, California, United States|37.9577,-121.29078
  • Torrance, California, United States|33.83585,-118.34063

Key Eligibility Criteria

  • Participants are eligible to be included in the study only if all of the following criteria apply:
  • Has newly diagnosed unresected Locally Advanced (LA) histologically confirmed HNSCC of the oral cavity, oropharynx, hypopharynx or larynx and compl…
  • Has provided acceptable core or excisional biopsy obtained prior to CRT:
  • PD-L1 positive tumor status

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Head and Neck Cancer Trials on Trialify →